Immune Safety Avatar
Nonclinical mimicking of the immune system effects of immunomodulatory therapies
The imSAVAR Vision
The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy.
The imSAVAR is an Innovative Medicines Initiative funded project that aims to develop a standard for integrated nonclinical safety overviews for immune-modulatory investigational new drugs (IND) and clinical trial applications (CTA).
Our imSAVAR platform will improve the prediction of the transferability of safety and efficacy of immunomodulators from pre-clinical models to first-in-human studies in collaboration with the private sector, pharma, regulators and technology providers. This joint effort not only benefits the field of immune safety evaluation, but will also generate various opportunities for European businesses as well as foster the meaningful engagement of multiple stakeholders including patients and regulators.
Upcoming Events
“If we really want to move forward with these modern immunomodulatory therapies we need much more research on predictive markers and predictive models. With the imSAVAR project we aim to tackle the challenge of a better understanding of the complexity of the human immune system.”
Ulrike Köhl / Coordinator
“The imSAVAR team plans to characterise a range of innovative human-relevant models and biomarkers to enhance translational safety assessment of immunomodulatory therapeutics and ultimately lead to the development of safer efficacious medicines for patients.”
Jonathan Moggs / Coordinator
Learn more about the imSAVAR project
Concept
Read more about our challenges, approach, objectives and the impact we want to make.
Consortium
The interdisciplinary imSAVAR consortium consists of 28 international partners from 11 nations.
Forum
Engage in lively discussions and help built up a strong imSAVAR stakeholder community.
Learn more about the imSAVAR project
Concept
Read more about our challenges, approach, objectives and the impact we want to make.
Consortium
The interdisciplinary imSAVAR consortium consists of 28 international partners from 11 nations.
Latest News
Register to join the workshop
The upcoming imSAVAR Stakeholder Workshop: Integrating Patient Preferences in Nonclinical Assessment of Immunomodulatory Therapies – Shifting the Paradigm will take place on 26 and 27 January 2021. Immune-related adverse
imSAVAR Stakeholder Survey: Views on Adverse Outcome Pathways & Model Grading Systems
The imSAVAR consortium selected four modes of action (MoAs)—CAR Ts, CPIs, BiTEs and IL-2 TREGs—needing better safety assessment models for its initial work. Model development and refinement for these
First paper on “Immunocompetent cancer-on-chip models” published!
The advances in cancer immunotherapy come with several roadblocks limiting their widespread use and their benefits to so far only a small subset of patients. The lack of representative